Onzetra Xsail is a drug owned by Currax Pharmaceuticals Llc. It is protected by 20 US drug patents filed from 2016 to 2023. Out of these, 15 drug patents are active and 5 have expired. Based on its patents and exclusivities, its generic launch date is estimated to be Oct 20, 2034. Details of Onzetra Xsail's patents and their expiration are given in the table below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| These drug patents focus on the other aspects of the drug like dosage, mode of administration (oral, tablet, capsules, liquids etc). | |||
| US10076614 | Nasal delivery devices |
Oct, 2034
(9 years from now) | Active |
| US10478574 | Nasal administration |
Nov, 2033
(8 years from now) | Active |
| US8978647 | Nasal delivery |
Dec, 2030
(6 years from now) | Active |
| US9649456 | Nasal administration |
Oct, 2030
(5 years from now) | Active |
| US8899229 | Powder delivery devices |
Aug, 2030
(5 years from now) | Active |
| US8550073 | Nasal delivery |
Oct, 2029
(4 years from now) | Active |
| US10076615 | Nasal delivery |
Jul, 2029
(4 years from now) | Active |
| US10722667 | Nasal administration |
Dec, 2028
(4 years from now) | Active |
| US8875704 | Nasal administration |
Apr, 2028
(3 years from now) | Active |
| US10398859 | Nasal delivery devices |
Dec, 2027
(3 years from now) | Active |
| US10124132 | Nasal delivery |
Mar, 2027
(2 years from now) | Active |
| US11571531 | Powder delivery devices |
Feb, 2026
(1 year, 3 months from now) | Active |
| US9108015 | Nasal delivery devices |
Sep, 2025
(9 months from now) | Active |
| US8590530 | Nasal delivery devices |
Sep, 2025
(9 months from now) | Active |
| US7975690 | Nasal devices |
Aug, 2025
(9 months from now) | Active |
| US9119932 | Nasal delivery device |
Apr, 2024
(6 months ago) |
Expired
|
| US8327844 | Nasal delivery method |
Oct, 2023
(1 year, 1 month ago) |
Expired
|
| US8047202 | Nasal devices |
Jul, 2023
(1 year, 4 months ago) |
Expired
|
| US6715485 | Nasal delivery device |
Mar, 2020
(4 years ago) |
Expired
|
| US8555877 | Nasal delivery device |
Mar, 2020
(4 years ago) |
Expired
|
A patent's expiry date may change depending upon legal activities going on that patent. Critical activities like abandoning of a patent, term extension of a patent or amendment of its claims can increase or decrease the life of a patent hence affecting its expiry date and in turn affecting the generic launch date of that drug. Tracking these ongoing activities on a patent application helps to keep an eye on the latest developments in the patent process of the drug which can give an idea of how early a drug's generic could be available. The next section provides a list of recent legal activities on Onzetra Xsail's patents.
Latest Legal Activities on Onzetra Xsail's Patents
Given below is the list of recent legal activities going on the following patents of Onzetra Xsail.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Payment of Maintenance Fee, 4th Year, Large Entity | 10 Jan, 2024 | US10722667 |
| Payment of Maintenance Fee, 4th Year, Large Entity | 19 May, 2023 | US10478574 |
| Payment of Maintenance Fee, 12th Year, Large Entity | 26 Apr, 2023 | US8047202 |
| Payment of Maintenance Fee, 8th Year, Large Entity | 15 Feb, 2023 | US9119932 |
| Payment of Maintenance Fee, 4th Year, Large Entity | 15 Feb, 2023 | US10398859 |
| Patent Issue Date Used in PTA Calculation Critical | 07 Feb, 2023 | US11571531 |
| Recordation of Patent Grant Mailed Critical | 07 Feb, 2023 | US11571531 |
| Payment of Maintenance Fee, 8th Year, Large Entity | 01 Feb, 2023 | US9108015 |
| Email Notification Critical | 19 Jan, 2023 | US11571531 |
| Issue Notification Mailed Critical | 18 Jan, 2023 | US11571531 |
Several oppositions have been filed on Onzetra Xsail's European patents. EP oppositions can significantly impact the timeline for the generic launch of drugs. If an opposition results in the revocation or amendment of a patent, it can shorten the exclusivity period of the original drug. This can lead to an earlier entry of generic versions into the market. To help you estimate the potential early arrival of Onzetra Xsail's generic, the next section provides detailed information on ongoing and past EP oppositions related to Onzetra Xsail patents.
Onzetra Xsail's Oppositions Filed in EPO
Onzetra Xsail has faced multiple oppositions in the European Patent Office. The earliest opposition was filed on Sep 27, 2005, by Direct-Haler A/S. This opposition was filed on patent number EP00906570A. Click below to reveal the latest opposition data.
| Application | Filing Date | Opposition Party | Legal Status |
|---|---|---|---|
 | |||
| EP08736896A | Jun, 2021 | Beck Greener LLP | Patent maintained as amended |
| EP13715145A | Sep, 2020 | ELKINGTON AND FIFE LLP | Granted and Under Opposition |
| EP00906570A | Sep, 2005 | Direct-Haler A/S | Opposition rejected |
US patents provide insights into the exclusivity only within the United States, but Onzetra Xsail is protected by patents in multiple countries. Understanding the full scope of patent protection is crucial in strategizing market entry. By looking at the broader patent landscape, you can identify markets with weaker patent protection which could be ideal generic entry points. The following section offers details on Onzetra Xsail's family patents as well as insights into ongoing legal events on those patents.
Onzetra Xsail's Family Patents
Explore Our Curated Drug Screens
Generic Launch
Generic Release Date:
Onzetra Xsail's generic launch date based on the expiry of its last outstanding patent is estimated to be Oct 20, 2034 (This date is subject to change depending upon the patent filing activities by the drug owner or exclusivity additions to its drug application)
Onzetra Xsail Generic API suppliers:
Sumatriptan Succinate is the generic name for the brand Onzetra Xsail. 29 different companies have already filed for the generic of Onzetra Xsail, with Mylan having the maximum number of approved applications. Check out the entire list of companies who have already received approval for Onzetra Xsail's generic
Alternative Brands for Onzetra Xsail
Onzetra Xsail which is used for acute treatment of migraines by delivering sumatriptan via a breath-powered nasal delivery device., has several other brand drugs using the same active ingredient (Sumatriptan Succinate). Given below is the list of those companies and their brand drugs, to help you identify new opportunities, assess competitors, and plan your market strategies more effectively.
| Drug Owner | Drug Name | |
|---|---|---|
| Currax |
| |
| Endo Operations |
| |
| Meridian Medcl |
| |
| Teva Branded Pharm |
| |
| Tonix Meds |
|
Apart from brand drugs containing the same ingredient, some generics have also been filed for Sumatriptan Succinate, Onzetra Xsail's active ingredient. Check the complete list of approved generic manufacturers for Onzetra Xsail
About Onzetra Xsail
Onzetra Xsail is a drug owned by Currax Pharmaceuticals Llc. It is used for acute treatment of migraines by delivering sumatriptan via a breath-powered nasal delivery device. Onzetra Xsail uses Sumatriptan Succinate as an active ingredient. Onzetra Xsail was launched by Currax in 2016.
Approval Date:
Onzetra Xsail was approved by FDA for market use on 27 January, 2016.
Active Ingredient:
Onzetra Xsail uses Sumatriptan Succinate as the active ingredient. Check out other Drugs and Companies using Sumatriptan Succinate ingredient
Treatment:
Onzetra Xsail is used for acute treatment of migraines by delivering sumatriptan via a breath-powered nasal delivery device.
Dosage:
Onzetra Xsail is available in powder form for nasal use. Given below is detailed information on Dosage -
| Strength | Dosage Form | Availability | Application Pathway |
|---|---|---|---|
| EQ 11MG BASE | POWDER | Prescription | NASAL |